IN THE UNITED STATES PATENT AND TRADEMARK OFFICE APR 2 6 2004 Before the Examiner Not yet known Serial No. 10/761,571 Group Art Unit Not yet known Filed January 21, 2004 NOVEL PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure in accordance with 37 CFR §1.56, Applicant wishes to bring to the attention of the Examiner the patents, publications and/or other information listed on the attached PTO Form 1449 (modified). Copies of the items are enclosed in accordance with 37 CFR §1.98.

The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b).

This Statement is being submitted more than three (3) months after the filing date of the application but before receipt of the first Office Action. It is believed that no fee is required for consideration of the submitted items. Should any fee be required, however, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

(Date of Deposit)

James B. Myers, Jr.

Name of Registered Representative

pul 21 2009

Date of Signature

Respectfully submitted,

By: James 1

James B. Myers Jr., Reg. No. 42,021 Woodard, Emhardt, Moriarty, McNett & Henry LLP

3700 Bank One Center Tower

111 Monument Circle

Indianapolis, IN 46204-5137

(317) 634-3456

APR 2 6 2004

Sheet

PTO/SB/08A (12/01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known 10/761,571 **Application Number** Substitute for form 1449A/PTO January 21, 2004 Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT GHOSH, Swapan K. First Named Inventor Group Art Unit (use as many sheets as necessary) **Examiner Name** 2 Attorney Docket No. 19026-14 1 of

		Document Number		T DOCUMENTS	Pages, Columns, Lines where
Examiner Initials*	Cite No. ¹	Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Relevant Passages or Relevant Figures Appear
_		4,439,425	03-27-1984	Tarcsay et al.	
		4,590,190	05-20-1986	Saito et al.	
		4,605,670	08-12-1986	Saito et al.	
		4,624,966	11-25-1986	Yamamoto et al.	
		4,752,612	06-21-1988	Saito et al.	
·		5,102,663	04-07-1992	Livingston et al.	
		5,122,598	06-16-1992	della Valle et al.	
		5,280,048	01-18-1994	Yamamoto et al.	
-		5,424,067	06-13-1995	Brancq et al.	
		5,449,670	09-12-1995	Skinner et al.	
		5,961,970	10-05-1999	Lowell et al.	
		6,063,380	05-16-2000	Chedid et al.	
		6,231,859	05-15-2001	Kensil	
		6,258,796	07-10-2001	Richards	
•		6,262,029	07-17-2001	Press et al.	
		6,261,573	07-17-2001	Loebelenz et al.	
		6,288,128	09-11-2001	Yamamoto et al.	
		6,299,884	10-09-2001	Van Nest et al.	
		US 2002/0082298	06-27-2002	Fluehmann et al.	
		6,451,325	09-17-2002	Van Nest et al.	
····		6,458,373	10-01-2002	Lambert et al.	
		6,525,035	02-25-2003	Danilov et al.	

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Le
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)				
		WO 02/083058	10-24-2002			
		WO 02/083122	10-24-2002			
		WO 03/013420	02-20-2003			
						Γ
Examiner S	ianotura			Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the ap0propriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (12/01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

ır	mber			Complete if Known			
Substitute for form 1449A/PTO				Application Number 10/761,571			
		א מות ו	CLOSUPE	Filing Date January 21, 2004			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	GHOSH, Swapan K.		
.)				Group Art Unit			
(use as many sheets as necessary)				Examiner Name			
Ż	Shoot 3	of	2	Attorney Docket No.	19026-14		

APR 2 6 2004

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T2
		Gupta, Rajesh K. et al., Adjuvantsa balance between toxicity and adjuvanticity, Vaccine, Vol. 11, Issue 3, 1993, pp. 293-306	
		O'Hagan, Derek T. et al., Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles, Molecular Medicine Today, February 1997, pp. 69-75	
		Sing, Manmohan et al., Advances in vaccine adjuvants, Nature Biotechnology, November 1999, Vol. 17, pp. 1075-1081	
11 S W ,		Neurath, A. Robert et al., Anti-HIV-I activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles, BMD Infectious Diseases April 30, 2002	
		Cribbs, David H. et al., Adjuvant-dependent modulation of $T_h 1$ and $T_h 2$ responses to immunization with β -amyloid, International Immunology, 2003, Vol. 15, No. 4, pp. 505-514	
			-
			-
	-		
			<u> </u>
			-
			-
			-
			-
-			

ĺ	Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the ap0propriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.